• No results found

[PDF] Top 20 Zoledronic acid in the management of metastatic bone disease

Has 10000 "Zoledronic acid in the management of metastatic bone disease" found on our website. Below are the top 20 most common "Zoledronic acid in the management of metastatic bone disease".

Zoledronic acid in the management of metastatic bone disease

Zoledronic acid in the management of metastatic bone disease

... to bone, usually unassociated with ...exposed bone in the maxillofacial area, poor wound healing, and ...or metastatic disease to the jaw, no uniform diagnostic criteria have been ... See full document

8

A scoping review on the surgical management of metastatic bone disease of the extremities

A scoping review on the surgical management of metastatic bone disease of the extremities

... with metastatic bone disease of the extrem- ities (MBD-E), breast cancer, lung cancer, renal cell can- cer, prostate cancer and multiple myeloma contributed to 78% of tumours in the Scandinavian ... See full document

10

Metastatic bone disease: Pathogenesis and therapeutic options: Up-date on bone metastasis management.

Metastatic bone disease: Pathogenesis and therapeutic options: Up-date on bone metastasis management.

... BM, bone metastases; BMD, bone mineral density; BMPs, bone morphogenetic proteins; BMSC, bone marrow stromal cells; BPs, bisphosphonates; BTA, bone targeting agents; BTM, bone ... See full document

13

Management of osteoporosis in the aging male: Focus on zoledronic acid

Management of osteoporosis in the aging male: Focus on zoledronic acid

... low bone mass are under-recognized and undertreated in ...of bone turnover, and decrease fracture risk in patients at high risk of ...Intravenous zoledronic acid may be a preferable ... See full document

15

Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management

Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management

... group. Zoledronic acid showed a faster and more persistent inhibitory effect on bone resorption markers than risedronate (Figure ...of bone formation mark- ers was higher in the ... See full document

17

Assessment of quality of life in patients with metastatic bone disease being treated with bisphosphonates and external beam radiation therapy

Assessment of quality of life in patients with metastatic bone disease being treated with bisphosphonates and external beam radiation therapy

... with Metastatic bone disease being treated with Bisphosphonates and EBRT” for a period of 6 months from October 2017 to March 2018 in Government General Hospital, Guntur in the Department of ... See full document

6

Optimal management of bone metastases in breast cancer patients

Optimal management of bone metastases in breast cancer patients

... in metastatic breast ...and zoledronic acid against placebo or against each ...new bone metastases, pathological fractures, spinal cord compression, irradiation of or surgery on bone, ... See full document

26

Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both: The TRAPEZE Randomized Clinical Trial.

Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both: The TRAPEZE Randomized Clinical Trial.

... collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for ... See full document

7

Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients

Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients

... Abstract: Bone loss is a common side effect of cancer treatments, especially antihormonal treatments used in the treatment of breast and prostate ...with metastatic disease to increasing bone ... See full document

8

A SYSTEMATIC REVIEW ON DIAGNOSIS AND MANAGEMENT OF POSTMENOPAUSAL OSTEOPOROSIS

A SYSTEMATIC REVIEW ON DIAGNOSIS AND MANAGEMENT OF POSTMENOPAUSAL OSTEOPOROSIS

... . Zoledronic Acid: Zoledronic acid is the most potent bisphosphonate available 74, 75 .... Zoledronic acid administered intravenously to postmenopausal women with osteoporosis at ... See full document

11

Curative Effect Analysis of Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis with Different Bone Turnover Rates

Curative Effect Analysis of Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis with Different Bone Turnover Rates

... metabolic bone diseases (MBDs) featuring a significant increase in bone reabsorption, especially those with a high turnover rate ...[6]. Zoledronic Acid, as a new-generation bisphosphonate, ... See full document

8

Metastatic Bone Disease - A Review of Literature

Metastatic Bone Disease - A Review of Literature

... and bone marrow suppression are identified as the major ...the bone are dynamic and always remain ...the bone and a variety of other factors like adolescent growth spurt, disease states, ... See full document

12

Estimated number of prevalent cases of metastatic bone disease in the US adult population

Estimated number of prevalent cases of metastatic bone disease in the US adult population

... of metastatic bone disease defined by at least one ICD-9-CM code for metastatic bone disease ...than bone cancer and a secondary diagnosis code for bone cancer ... See full document

7

The present and future role of bisphosphonates in the management of patients with breast cancer

The present and future role of bisphosphonates in the management of patients with breast cancer

... bisphosphonates, zoledronic acid and ibandronate, suggest that they may soon find a place in routine ...therapy. Zoledronic acid, which is given intravenously, shows much greater potency than ... See full document

6

Survival Rates Following Skeletal Metastases—A Twenty Year Analysis

Survival Rates Following Skeletal Metastases—A Twenty Year Analysis

... elevated bone-specific alkaline phosphatase (ALP), haemoglobin (Hb) of less than 7 mmol/L and hypercalcaemia have been identified as negative prognostic factors [1] ...the management of patients with ... See full document

9

Zoledronic acid in metastatic osteosarcoma: encouraging progression free survival in four consecutive patients

Zoledronic acid in metastatic osteosarcoma: encouraging progression free survival in four consecutive patients

... Background: Zoledronic acid (ZA) is a third-generation bisphosphonate in widespread clinical use to reduce pain and skeletal events in patients from a variety of malignancies with bone ... See full document

7

Multiple Myeloma associated Bone Disease

Multiple Myeloma associated Bone Disease

... and zoledronic acid, but a higher incidence of hypocalcemia was observed among patients treated with ...with bone metastases and severe renal insufficiency, denosumab can be given, but causes an ... See full document

24

Importance of antiresorptive therapies for patients with bone metastases from solid tumors

Importance of antiresorptive therapies for patients with bone metastases from solid tumors

... The medical care team can play an important role in edu- cating the patient regarding the importance of antiresorptive therapy when cancer has metastasized to bone. Medical care for patients with cancer requires ... See full document

11

TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.

TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.

... The previously defined log-rank time-to-event analysis took into account only the time-to-first SRE, although patients were at risk of experiencing multiple SREs throughout the course of the trial. It was, therefore, ... See full document

324

Original Article Pain care nursing ameliorates the psychological burden and improves the efficacy in combined treatment of radiotherapy and zoledronic acid for bone metastasis of malignant tumor

Original Article Pain care nursing ameliorates the psychological burden and improves the efficacy in combined treatment of radiotherapy and zoledronic acid for bone metastasis of malignant tumor

... Analysis of our results suggested that these two nursing methods can improve the scores of anxiety and depression of patients, but patients receiving the pain care nursing gained more improvement than those receiving the ... See full document

7

Show all 10000 documents...